112 related articles for article (PubMed ID: 20727918)
1. uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954.
Prosser GA; Patterson AV; Ackerley DF
J Biotechnol; 2010 Oct; 150(1):190-4. PubMed ID: 20727918
[TBL] [Abstract][Full Text] [Related]
2. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
[TBL] [Abstract][Full Text] [Related]
3. Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954.
Jarrom D; Jaberipour M; Guise CP; Daff S; White SA; Searle PF; Hyde EI
Biochemistry; 2009 Aug; 48(32):7665-72. PubMed ID: 19580253
[TBL] [Abstract][Full Text] [Related]
4. Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954.
Race PR; Lovering AL; White SA; Grove JI; Searle PF; Wrighton CW; Hyde EI
J Mol Biol; 2007 Apr; 368(2):481-92. PubMed ID: 17350040
[TBL] [Abstract][Full Text] [Related]
5. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel nitroreductases from Bacillus cereus and their interaction with the CB1954 prodrug.
Gwenin VV; Poornima P; Halliwell J; Ball P; Robinson G; Gwenin CD
Biochem Pharmacol; 2015 Dec; 98(3):392-402. PubMed ID: 26415543
[TBL] [Abstract][Full Text] [Related]
7. Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle.
Guise CP; Grove JI; Hyde EI; Searle PF
Gene Ther; 2007 Apr; 14(8):690-8. PubMed ID: 17301844
[TBL] [Abstract][Full Text] [Related]
8. E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.
Mitchell DJ; Minchin RF
Cancer Gene Ther; 2008 Nov; 15(11):758-64. PubMed ID: 18600257
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of CB1954 reduction by Escherichia coli nitroreductase.
Christofferson A; Wilkie J
Biochem Soc Trans; 2009 Apr; 37(Pt 2):413-8. PubMed ID: 19290872
[TBL] [Abstract][Full Text] [Related]
10. Directed evolution of the B. subtilis nitroreductase YfkO improves activation of the PET-capable probe SN33623 and CB1954 prodrug.
Rich MH; Sharrock AV; Ashoorzadeh A; Patterson AV; Smaill JB; Ackerley DF
Biotechnol Lett; 2021 Jan; 43(1):203-211. PubMed ID: 32851465
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.
Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235
[TBL] [Abstract][Full Text] [Related]
12. Nitroreductase from Bacillus licheniformis: a stable enzyme for prodrug activation.
Emptage CD; Knox RJ; Danson MJ; Hough DW
Biochem Pharmacol; 2009 Jan; 77(1):21-9. PubMed ID: 18840409
[TBL] [Abstract][Full Text] [Related]
13. E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.
Vass SO; Jarrom D; Wilson WR; Hyde EI; Searle PF
Br J Cancer; 2009 Jun; 100(12):1903-11. PubMed ID: 19455141
[TBL] [Abstract][Full Text] [Related]
14. E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy.
Blackwood L; O'Shaughnessy PJ; Reid SW; Argyle DJ
Vet J; 2001 May; 161(3):269-79. PubMed ID: 11352484
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of NfsA-like nitroreductases from Neisseria meningitidis and Bartonella henselae for enzyme-prodrug therapy, targeted cellular ablation, and dinitrotoluene bioremediation.
Rich MH; Sharrock AV; Hall KR; Ackerley DF; MacKichan JK
Biotechnol Lett; 2018 Feb; 40(2):359-367. PubMed ID: 29147875
[TBL] [Abstract][Full Text] [Related]
16. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite.
Bridgewater JA; Knox RJ; Pitts JD; Collins MK; Springer CJ
Hum Gene Ther; 1997 Apr; 8(6):709-17. PubMed ID: 9113510
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of the UvrABC nucleotide excision repair proteins analyzed by fluorescence resonance energy transfer.
Malta E; Moolenaar GF; Goosen N
Biochemistry; 2007 Aug; 46(31):9080-8. PubMed ID: 17630776
[TBL] [Abstract][Full Text] [Related]
18. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy.
Bailey SM; Knox RJ; Hobbs SM; Jenkins TC; Mauger AB; Melton RG; Burke PJ; Connors TA; Hart IR
Gene Ther; 1996 Dec; 3(12):1143-50. PubMed ID: 8986441
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954.
Fu Y; Buryanovskyy L; Zhang Z
Biochem Biophys Res Commun; 2005 Oct; 336(1):332-8. PubMed ID: 16129418
[TBL] [Abstract][Full Text] [Related]
20. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.
Grove JI; Lovering AL; Guise C; Race PR; Wrighton CJ; White SA; Hyde EI; Searle PF
Cancer Res; 2003 Sep; 63(17):5532-7. PubMed ID: 14500391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
